433 related articles for article (PubMed ID: 27795534)
21. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
23. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
24. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.
Dolan DE; Gupta S
Cancer Control; 2014 Jul; 21(3):231-7. PubMed ID: 24955707
[TBL] [Abstract][Full Text] [Related]
25. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
26. Clinical Development of Immune Checkpoint Inhibitors.
Ito A; Kondo S; Tada K; Kitano S
Biomed Res Int; 2015; 2015():605478. PubMed ID: 26161407
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
28. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
Sui X; Ma J; Han W; Wang X; Fang Y; Li D; Pan H; Zhang L
Oncotarget; 2015 Aug; 6(23):19393-404. PubMed ID: 26305724
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
30. [Immune Checkpoint Inhibitors for Advanced Melanoma - Evidences and Future Perspectives].
Nakamura Y; Teramoto Y; Asami Y; Matsuya T; Yamamoto A
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1036-40. PubMed ID: 27628544
[TBL] [Abstract][Full Text] [Related]
31. PD-1 and PD-L1 antibodies in cancer: current status and future directions.
Balar AV; Weber JS
Cancer Immunol Immunother; 2017 May; 66(5):551-564. PubMed ID: 28213726
[TBL] [Abstract][Full Text] [Related]
32. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
33. Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long L; Zhao C; Ozarina M; Zhao X; Yang J; Chen H
Clin Drug Investig; 2019 Apr; 39(4):341-353. PubMed ID: 30778885
[TBL] [Abstract][Full Text] [Related]
34. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
Eigentler TK; Hassel JC; Berking C; Aberle J; Bachmann O; Grünwald V; Kähler KC; Loquai C; Reinmuth N; Steins M; Zimmer L; Sendl A; Gutzmer R
Cancer Treat Rev; 2016 Apr; 45():7-18. PubMed ID: 26922661
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
[TBL] [Abstract][Full Text] [Related]
39. [Anti-PD-1 Antibody Drugs - Potential of Plasma PD-L1 Protein as a Biomarker].
Iinuma H; Matsutani N; Uehara H; Kawamura M
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1030-5. PubMed ID: 27628543
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors: a patent review (2010-2015).
Collin M
Expert Opin Ther Pat; 2016 May; 26(5):555-64. PubMed ID: 27054314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
